Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants

References

1. Aspden K., Passmore J.-A., Tiedt F., Williamson A.-L. 2003; Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J Gen Virol 84:1985–1996 [CrossRef]
   [Google Scholar]
2. Barcena J., Morales M., Vazquez B., Boga J. A., Parra F., Lucientes J., Pages-Mante A., Sanchez-Vizcaino J. M., Blasco R., Torres J. M. 2000; Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus. J Virol 74:1114–1123 [CrossRef]
   [Google Scholar]
3. Bertagnoli S., Gelfi J., Le Gall G., Boilletot E., Vautherot J., Rasschaert D., Laurent S., Petit F., Boucraut-Baralon C., Milon A. 1996; Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein. J Virol 70:5061–5066
   [Google Scholar]
4. Boone J. D., Balasuriya U. B., Karaca K., Audonnet J. C., Yao J., He L., Nordgren R., Monaco F., Savini G. other authors 2007; Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25:672–678 [CrossRef]
   [Google Scholar]
5. Boyle D. B., Coupar B. E. H. 1988; A dominant selectable marker for construction of recombinant poxviruses. Gene 65:123–128 [CrossRef]
   [Google Scholar]
6. Carroll M. W., Moss B. 1997; Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198–211 [CrossRef]
   [Google Scholar]
7. Chahroudi A., Chavan R., Koyzr N., Waller E. K., Silvestri G., Feinberg N. B. 2005; Vaccinia virus tropism for hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79:10397–10407 [CrossRef]
   [Google Scholar]
8. Chantal J., Bertagnoli S. 2004; Myxomatosis. In Manual for Diagnostic Tests and Vaccines for Terrestrial Animals vol II, 5th edn. Paris: OIE;
   [Google Scholar]
9. Collin N., Guérin J. L., Drexler I., Blanié S., Gelfi J., Boullier S., Foucras G., Sutter G., Messud-Petit F. 2005; The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I molecules. Virology 343:171–178 [CrossRef]
   [Google Scholar]
10. Fenner F., Ross J. 1994; Myxomatosis. In The European Rabbit, the History and Biology of a Successful Colonizer . pp 205–239Edited by Thompson G. V., King C. M. New York: Oxford University Press;
11. Guérin J. L., Gelfi J., Camus C., Delverdier M., Whisstock J. C., Amardeidhl M. F., Py R., Bertagnoli S., Messud-Petit F. 2001; Characterization and functional analysis of Serp3: a novel myxoma virus-encoded serpin involved in virulence. J Gen Virol 82:1407–1417
    [Google Scholar]
12. Guérin J. L., Gelfi J., Boullier S., Delverdier M., Bellanger F. A., Bertagnoli S., Drexler I., Sutter G., Messud-Petit F. 2002; Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins. J Virol 76:2912–2923 [CrossRef]
    [Google Scholar]
13. Johnston J. B., Nazarian S. H., Natale R., McFadden G. 2005; Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses. Virology 332:235–248 [CrossRef]
    [Google Scholar]
14. Lalani A. S., Masters J., Zeng W., Barrett J., Pannu R., Everett H., Arendt C. W., McFadden G. 1999; Use of chemokine receptors by poxviruses. Science 286:1968–1971 [CrossRef]
    [Google Scholar]
15. Macen J. L., Graham K. A., Lee S. F., Schreiber M., Boshkov L. K., McFadden G. 1996; Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 218:232–237 [CrossRef]
    [Google Scholar]
16. Mansouri M., Bartee E., Gouveia K., Hovey Nerenberg B. T., Barrett J., Thomas L., Thomas G., McFadden G., Fruh K. 2003; The PHD/LAP-domain protein M153R of myxoma virus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J Virol 77:1427–1440 [CrossRef]
    [Google Scholar]
17. McCabe V. J., Spibey N. 2005; Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein. Vaccine 23:5380–5388 [CrossRef]
    [Google Scholar]
18. McCabe V. J., Tarpey I., Spibey N. 2002; Vaccination of cats with an attenuated myxoma virus expressing feline calicivirus capsid protein. Vaccine 20:2454–2462 [CrossRef]
    [Google Scholar]
19. Moss B. 2001; Poxviridae : the viruses and their replication. In Virology, 4th edn. pp 2849–2883Edited by Knipe D. M., Howley. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
20. Moss B., Carroll M. W., Wyatt L. S., Bennink J. R., Hirsch V. M., Goldstein S., Elkins W. R., Fuerst T. R., Lifson J. D. other authors 1996; Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397:7–13
    [Google Scholar]
21. Opgenorth A., Graham K., Nation N., Strayer D., McFadden G. 1992; Deletion analysis of two tandemly arranged virulence genes in myxoma virus. M11L and myxoma virus growth factor. J Virol 66:4720–4731
    [Google Scholar]
22. Pignolet B., Duteyrat J. L., Allemandou A., Gelfi J., Foucras G., Bertagnoli S. 2007; In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains. Virol J 4:94 [CrossRef]
    [Google Scholar]
23. Redfield R. R., Wright D. C., James W. D., Jones T. S., Brown C., Burke D. C. 1987; Disseminated vaccinia in military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316:673–676 [CrossRef]
    [Google Scholar]
24. Saurat P., Gilbert Y., Ganière J.-P. 1978; Etude d'une souche de virus myxomateux modifié. Rev Med Vet 129:415–451 (in French
    [Google Scholar]
25. Sutter G., Moss B. 1992; Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89:10847–10851 [CrossRef]
    [Google Scholar]
26. Sypula J., Wang F., Ma Y., Bell J., McFadden G. 2004; Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 8:103–114
    [Google Scholar]
27. Tartaglia J., Jarrett O., Neil J. C., Desmettre P., Paoletti E. 1993; Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 67:2370–2375
    [Google Scholar]
28. Taylor J., Paoletti E. 1988; Fowlpox virus as a vector in non-avian species. Vaccine 6:466–468 [CrossRef]
    [Google Scholar]
29. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. 1988; Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6:497–503 [CrossRef]
    [Google Scholar]
30. Wang F., Ma Y., Barrett J. W., Gao X., Loh J., Barton E., Virgin H. W., McFadden G. 2004; Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 5:1266–1274 [CrossRef]
    [Google Scholar]
31. Wang G., Barrett J. W., Stanford M., Werden S. J., Johnston J. B., Gao X., Sun M., Cheng J. Q., McFadden G. 2006; Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 103:4640–4645 [CrossRef]
    [Google Scholar]
32. WHO (World Health Organization) 1980; The Global Eradication of Smallpox. Final Report of the Global Commission for the Certification of Smallpox Eradication . History of International Public Health no: 4 Geneva: World Health Organization;
    [Google Scholar]